DSIP Research Overview (also known as Delta Sleep-Inducing Peptide)
A naturally occurring neuropeptide studied for its influence on sleep architecture, deep-sleep stage regulation, and nighttime cortisol reduction. Research has focused on improving restorative sleep quality and supporting recovery in high-cortisol research models.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is DSIP?
Delta Sleep Inducing Peptide (DSIP) is a nonapeptide first isolated from cerebral venous blood of rabbits in a state of slow-wave sleep in 1974. Despite its name, DSIP has since been found to exert a remarkably diverse range of biological effects across neuroendocrine, cardiovascular, and stress-response systems.
Sleep Regulation
DSIP's founding property — induction of delta (slow-wave) sleep — is mediated through interactions with the sleep regulatory system. It modulates hypothalamic sleep centers, interacts with serotonergic and opioidergic systems governing sleep-wake cycling, and has been shown to reduce sleep latency and increase the proportion of deep non-REM sleep. Unlike pharmacological sleep aids, it does not produce sedation during waking hours or rebound insomnia.
Stress and Opioid Withdrawal Research
DSIP demonstrates capacity to normalize cortisol secretion and attenuate stress-induced HPA axis responses — generating research interest for stress-related sleep disorders. One of the more striking applications is attenuation of opioid withdrawal symptoms: studies in both animal models and small human trials have shown DSIP reduces withdrawal severity, potentially through interactions with endogenous opioid receptor systems and stress-axis normalization.
Quick Reference
| Literature-Reported Dose Range | 100–300 mcg per injection |
| Literature-Reported Frequency | Once daily, 30-60 minutes before bed |
| Literature-Reported Cycle Length | 5-10 consecutive days |
| Literature-Reported Washout | 2-4 weeks between cycles |
| Storage | Refrigerate at 2-8°C, protect from light, use within 14 days |
| Sites Reported in Studies | Subcutaneous: abdomen, thigh, upper arm |
| Timing | Evening administration 30-60 minutes before intended sleep |
Research Indications
Sleep
Deep Sleep Enhancement
Promotes delta wave sleep, the most restorative sleep phase for physical recovery
Sleep Efficiency
Reduces sleep latency and nocturnal awakenings without morning grogginess
Natural Sleep Architecture
Supports natural sleep cycles rather than forcing sedation like traditional sleep aids
Mood
Stress Response Modulation
Regulates cortisol and ACTH release, buffering against chronic stress
Mood Stabilization
Increases serotonin and endorphin production for improved emotional balance
Anxiety Reduction
Calms overactive stress pathways without sedative side effects
Metabolic
Pain Modulation
Analgesic effects through endogenous opioid system interaction
Hormonal Balance
Influences growth hormone, LH, and other endocrine functions
Withdrawal Support
Clinical use in alcohol and opioid withdrawal symptom management
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Sleep Enhancement | 100-200mcg | Once nightly | SubQ |
| Chronic Pain | 250-300mcg | Daily | IV or SubQ |
| Stress Management | 150mcg | Evening | SubQ |
| Withdrawal Support | 200-300mcg | Twice daily | IV preferred |
| Athletic Recovery | 100-150mcg | Post-training | SubQ |
Timing
Recommended administration window: evening administration 30-60 minutes before intended sleep. Typical onset: sleep pressure: 30-60 min, Deep sleep: first night, Full benefits: 3-5 days.
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
Both regulate sleep-wake cycles - DSIP enhances slow-wave sleep while melatonin regulates circadian rhythm, creating complementary sleep benefits
DSIP enhances GABA activity - monitor for excessive sedation when combining with benzodiazepines or other GABA modulators
DSIP helps regulate cortisol - can be used alongside adaptogenic compounds for comprehensive stress management
Different mechanisms - Semax for daytime cognition, DSIP for nighttime recovery, creating 24-hour optimization
DSIP may modulate opioid receptors and has been used in withdrawal - professional supervision required with opioid medications
No direct interaction - DSIP may support natural GH release during sleep without interfering with GH peptides
Reported Research Timeline
01First dose (reported in cited studies): noticeable sleep pressure and easier sleep onset
02Night 1-3: Deeper sleep, fewer awakenings, vivid dreams possible
03Day 2–5 (reported in cited studies): improved morning refreshment, stable daytime energy
04Day 5–10 (reported in cited studies): cumulative stress reduction, mood improvements
05Post-cycle: Benefits may persist 1-2 weeks after stopping
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Generally well-tolerated with minimal side effects
Some users report mild drowsiness or dizziness initially
Occasional reports of headaches in sensitive individuals
No tolerance or dependence reported in studies
Avoid driving until effects are known
Not recommended during pregnancy or breastfeeding
Seek Medical Attention If:
Excessive daytime sedation
Paradoxical insomnia or agitation
Mood changes or depression
Unusual dreams causing distress
Quality Indicators
Verified Marker
White lyophilized powder
Pure DSIP appears as white to off-white powder before reconstitution
Verified Marker
Clear solution when mixed
Properly reconstituted DSIP should be completely clear and colorless
Acceptable Range
Short stability period
DSIP has limited stability - use reconstituted solution within 14 days
Quality Concern
Yellow or cloudy solution
Indicates degradation or contamination - do not use
Verified Marker
Reputable source essential
Due to instability, source quality is critical - verify third-party testing
Acceptable Range
Protect from degradation
DSIP degrades quickly - minimize light exposure and temperature fluctuations
Research Citations
- Stroke Recovery in Rats (2021)
Rats | 120 μg/kg nasal | 7 days | Enhanced motor recovery - Chronic Insomnia Double-Blind Study (1991)
Human | 15-30 nmol | 6 consecutive nights | Improved sleep efficiency - Endocrine Modulation Research (1988)
Human/Animal | Various doses | Multiple studies | Hormone regulation - Chronic Pain Pilot Study (1984)
Human | 25 nmol IV | 10 days | 6/7 patients improved - Alcohol and Opioid Withdrawal (1984)
Human | Variable doses | 5-10 days | Symptom reduction - Sleep Pressure Induction Study (1983)
Human | 25 nmol/kg IV | Single dose | 59% sleep increase - Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Kovalzon VM, Strekalova TV, 2006, J Neurochem - Delta-sleep-inducing peptide (DSIP): an update
Graf MV, Kastin AJ, 1986, Peptides - The effect of delta sleep-inducing peptide (DSIP) and phosphorylated DSIP (P-DSIP) on the apomorphine-induced hypothermia in rats
Tsunashima K, Masui A, Kato N, 1990, Brain Res - Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models
Mu X, Qu L, Yin L, 2024, Front Pharmacol - Delta sleep-inducing peptide (DSIP)-like immunoreactivity in gut: coexistence with known peptide hormones
Bjartell A, Ekman R, Hedenbro J, 1989, Peptides
Research Focus
Sleep regulation, Stress reduction, Opioid withdrawal, Delta sleep induction, Neuroprotection
Verified Vendors Carrying DSIP
Frequently Asked Questions
What should researchers watch for with DSIP?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with DSIP?
First dose (reported in cited studies): noticeable sleep pressure and easier sleep onset
How is DSIP typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →